UpDoc

K253281 · Updoc, Inc. · NDC · Dec 23, 2025 · Anesthesiology

Device Facts

• Record ID: K253281
• Device Name: UpDoc
• Applicant: Updoc, Inc.
• Product Code: NDC · Anesthesiology
• Decision Date: Dec 23, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 868.1890
• Device Class: Class 2
• Attributes: Software as a Medical Device, Therapeutic, PCCP

Intended Use

UpDoc is a software as a medical device (SaMD) intended to provide medication management for patients aged 18 years and older who have been diagnosed with type 2 diabetes. UpDoc provides patients with insulin treatment plan instructions based on a healthcare provider-specified treatment plan. UpDoc contains two user-interactive software components: Patient User Interface (UpDoc mobile application): Intended for use by patients with type 2 diabetes as an aid in optimizing insulin management. Patients use the mobile application to log blood glucose, meal, symptom, and medication adherence data, and receive treatment plan instructions. Data may be entered manually or reported via voice or text-based interactions. The application may also receive blood glucose data via a Bluetooth-enabled glucometer or continuous glucose monitor. Healthcare Provider User Interface (UpDoc web portal): Intended for use by trained healthcare providers to configure and manage the patient-specific insulin treatment plan. This includes insulin dosing instructions (type, starting and maximum doses, adjustment algorithm, and blood glucose targets) and safety protocols to address non-emergency hypoglycemia, hyperglycemia, and related symptoms. Insulin instructions are computed in UpDoc’s cloud-based application based on the healthcare provider-defined treatment parameters.

Device Story

UpDoc is a cloud-based SaMD for type 2 diabetes insulin management. Inputs include patient-reported blood glucose (manual, voice, text, or Bluetooth-connected CGM/glucometer), meal data, medication adherence, and symptom logs. HCPs use a web portal to configure individualized treatment plans, including insulin types, dosing targets, and safety protocols. The cloud-based Clinical Service computes insulin instructions based on these HCP-defined parameters. The patient mobile app delivers these instructions and provides safety alerts (e.g., eat something sweet, contact provider). The system includes safety locks that trigger if newly reported symptoms or non-protocol-compliant data are detected, preventing inappropriate dose increases. The device supports HCPs by providing longitudinal data logs and treatment history. It benefits patients by facilitating adherence to provider-directed insulin titration and improving safety through automated symptom-based system locks.

Clinical Evidence

No clinical testing was performed. Substantial equivalence is supported by non-clinical testing, including software verification/validation per IEC 62304, cybersecurity assessment, and human factors/usability engineering.

Technological Characteristics

SaMD architecture comprising a patient mobile app, provider web portal, and cloud-based Clinical Service. Operates via deterministic insulin titration algorithms based on HCP-defined parameters. Connectivity includes Bluetooth for glucose monitor integration. Software classified as major level of concern. Complies with IEC 62304, cybersecurity guidance, and human factors standards.

Indications for Use

Indicated for patients aged 18+ with type 2 diabetes to provide insulin treatment plan instructions. Contraindicated for patients with type 1 diabetes.

Regulatory Classification

Identification

A predictive pulmonary-function value calculator is a device used to calculate normal pulmonary-function values based on empirical equations.

Predicate Devices

• d-Nav System (K181916)

Submission Summary (Full Text)

{0}

FDA

U.S. FOOD & DRUG

ADMINISTRATION

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

## I Background Information:

A 510(k) Number

K253281

B Applicant

UpDoc, Inc.

C Proprietary and Established Names

UpDoc (01-00-US)

D Regulatory Information

| Product Code(s) | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| NDC | Class II | 21 CFR 868.1890 - Predictive pulmonary-function value calculator | Clinical Chemistry |

## E Purpose for Submission:

- New device
- Establish a Predetermined Change Control Plan (PCCP)

## II Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

B Indication(s) for Use:

UpDoc is a software as a medical device (SaMD) intended to provide medication management for patients aged 18 years and older who have been diagnosed with type 2 diabetes.

UpDoc provides patients with insulin treatment plan instructions based on a healthcare provider-specified treatment plan.

UpDoc contains two user-interactive software components:

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{1}

- Patient User Interface (UpDoc mobile application): Intended for use by patients with type 2 diabetes as an aid in optimizing insulin management. Patients use the mobile application to log blood glucose, meal, symptom, and medication adherence data, and receive treatment plan instructions. Data may be entered manually or reported via voice or text-based interactions. The application may also receive blood glucose data via a Bluetooth-enabled glucometer or continuous glucose monitor.

- Healthcare Provider User Interface (UpDoc web portal): Intended for use by trained healthcare providers to configure and manage the patient-specific insulin treatment plan. This includes insulin dosing instructions (type, starting and maximum doses, adjustment algorithm, and blood glucose targets) and safety protocols to address non-emergency hypoglycemia, hyperglycemia, and related symptoms.

Insulin instructions are computed in UpDoc’s cloud-based application based on the healthcare provider-defined treatment parameters.

## C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only.

UpDoc should not be used in the following situations:

- Patients with type 1 diabetes

## III Device Description

UpDoc is a software as a medical device (SaMD) designed to assist patients aged 18 years and older with insulin management for type 2 diabetes. Healthcare providers (HCPs) set an individualized treatment plan for their patients that includes monitoring and insulin titration instructions. UpDoc engages with patients to help them follow their designated treatment plan and supports HCPs in monitoring reported health data, medication adherence, and treatment progress.

UpDoc is composed of three modular software components: a provider-facing web portal (UpDoc Provider Portal), a patient mobile application (UpDoc Patient App), and a cloud-based application consisting of a Conversation Service (UpDoc Agent) and a Clinical Service. These components work together to support safe and effective provider-directed insulin therapy.

## IV Substantial Equivalence Information:

### A Predicate Device Name(s):

d-Nav System

### B Predicate 510(k) Number(s):

K181916

K253281 - Page 2 of 6

{2}

# C Comparison with Predicate(s):

| Device & Predicate Device(s): | K253281 | K181916 |
| --- | --- | --- |
| Device Trade Name | UpDoc | d-Nav System |
| General Device Characteristic Similarities | | |
| Intended Use/Indications For Use | UpDoc is a software as a medical device (SaMD) intended to provide medication management for patients aged 18 years and older who have been diagnosed with type 2 diabetes. UpDoc provides patients with insulin treatment plan instructions based on a healthcare provider (HCP)-specified treatment plan. | Same |
| Intended Users | • Health Care Provider (HCP) • Patients with Type 2 diabetes | Same |
| Use Environments | Healthcare settings and home environments | Same |
| Rx/OTC | Rx | Same |
| General Device Characteristic Differences | | |
| Supported Insulin | • Glargine U-100 • Glargine U-300 • Degludec U-100 • Degludec U-200 • NPH • Regular Insulin U-100 • Insulin Aspart • Insulin Glulisine • Insulin Lispro • Humulin 70/30 • Novolin 70/30 | • Lantus • Basaglar • Tresibo • Toujeo • Humalog • NovoLog • Apidra • Humalog Mix 75/25 • Novolog Mix 70/30 • Humulin 70/30 |

K253281 - Page 3 of 6

{3}

K253281 - Page 4 of 6

| | • Humalog Mix 75/25
• Humalog Mix 50/50
• Novolog Mix 70/30 | • Novolin 70/30 |
| --- | --- | --- |

In addition to the similarities and differences between the candidate and predicate devices listed in the table above, the candidate device has an authorized PCCP to make specific adjustments to default values or clinical definitions, update insulin product references, add insulin dosing features, make user interface/user experience enhancements, and implement alternative data input methods. See Section VI.C for more information.

## V Standards/Guidance Documents Referenced:

IEC 62304 and FDA's guidance Content of Premarket Submissions for Device Software Functions

FDA's guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions

FDA's guidance Applying Human Factors and Usability Engineering to Medical Devices

## VI Performance Characteristics:

### A. Non-Clinical Performance

Not applicable.

### B. Clinical Studies:

Not applicable.

### C. Other Supportive Instrument Performance Characteristics Data

#### Usability:

The sponsor provided comprehensive human factors engineering protocols and study results demonstrating that intended users can safely and effectively perform all critical tasks associated with the modified device features. The study participants were representative of the device's intended user population, including:

- Patients - adults over 18 years of age with type 2 diabetes across varying levels of technology experience and diabetes management proficiency
- Healthcare providers - qualified clinicians responsible for diabetes care management and treatment plan configuration

The human factors validation studies adequately demonstrated that users can operate the device safely without use-related errors that could compromise patient safety or treatment effectiveness. The results support a determination of substantial equivalence to the predicate device regarding usability and user interface design.

{4}

Software:

The sponsor provided comprehensive software documentation in accordance with FDA's "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" (May 11, 2005). The documentation was consistent with the requirements for software classified as having a major level of concern, reflecting the device's potential impact on patient safety through insulin dosing recommendations.

The software documentation package included appropriate:

- Software requirements and design specifications demonstrating traceability between intended use and software functionality
- Verification and validation protocols with evidence of comprehensive testing across anticipated use scenarios
- Risk analysis and mitigation strategies addressing potential software-related hazards and their clinical implications
- Cybersecurity considerations appropriate for the device's connectivity and data handling capabilities

The submitted software documentation was determined to be acceptable and sufficient to support the safety and effectiveness determination for this 510(k) submission.

Predetermined Change Control Plan (PCCP):

The sponsor proposes the following six categories of modifications in their PCCP plan:

1. Specific adjustments to default values or clinical definitions
a. Adjusting the default goal fasting blood glucose range for titration
b. Modifying the number of blood glucose readings used to calculate an average
c. Updating the maximum configurable insulin dose
d. Modifying system-recognized symptom definitions (e.g., "hypoglycemia symptoms")

2. Updates to insulin product references
a. Adding references to newly approved FDA insulin formulations or biosimilars
b. Updating insulin-specific dosing ranges in alignment with clinical practice guidelines

3. Addition of insulin-dosing features
a. Supporting meal-related delivery logic (e.g., carb counting, pre-meal BG corrections)
b. Supporting insulin sliding scales

4. User Interface (UI)/User eXperience (UX) enhancements (e.g., multilingual support, iconography, or layout adjustments).
a. Addition of language support (e.g., Spanish, Mandarin) for patient instructions and app UI
b. Modification of provider portal layout or visualizations to improve workflow efficiency (e.g., summary dashboards, filter tools)
c. Changes to patient app appearance (e.g., colors, icons, glucose graph display) that improve usability without affecting functionality

K253281 - Page 5 of 6

{5}

K253281 - Page 6 of 6

5. Alternative data input methods
a. Obtaining an existing input (e.g., blood glucose readings, insulin adherence data) via a new method or channel (e.g., Apple HealthKit, new CGM interface, external log)
b. Supporting alternate patient-reported adherence input methods (e.g., external logs instead of voice input)
c. Enabling additional input modes (e.g., voice commands, tap-to-log, device syncing)

As part of this PCCP, UpDoc will verify the updated software following a testing framework that includes automated unit testing, integration testing, and regression testing with 100% pass rate requirements across all modification categories. Validation activities encompass clinical governance review by subject matter experts, technical review for compatibility assessment, and risk-based human factors evaluations. Performance requirements mandate that all modifications maintain deterministic insulin dosing logic without altering core clinical decision-making, preserve system accuracy and response times, and ensure data imported from alternative sources matches manually entered values exactly with zero tolerance for deviation and incorrect unit conversion rates of zero.

Users will be notified of modifications through multiple channels including change summaries made available in both the UpDoc Provider Portal and Patient App, updated labeling and Instructions for Use documentation, brief in-app guided tours for significant layout changes, and comprehensive training materials including FAQs and training modules for healthcare providers when new features are introduced. The system ensures transparency through formal documentation within the Quality Management System, traceability matrices linking modifications to their rationale and validation activities, and maintenance of detailed change control records that provide full audit trails for regulatory compliance and user awareness.

VII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

VIII Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.